Lead Sponsor

Bristol-Myers Squibb

Collaborators

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
•Women and men ≥ 18 years of age.
•Histologic confirmation of renal cell carcinoma with a clear cell component.
•Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST).
•Tumor sites that can be accessed for repeat biopsies at acceptable clinical risk.
•Previously treated subjects must have failed at least 1 prior anti-angiogenic agent and can have a maximum of 3 prior systemic treatments for renal cell cancer.
•Subjects in the treatment naive arm cannot have received prior systemic therapy for their renal cell carcinoma.

•Active or progressing brain metastases.
•Active concomitant.
•Active or history of autoimmune disease.
•Active use of systemic corticosteroids.
•Prior therapy with Cytotoxic T lymphocyte-associated antigen 4 (anti-CTLA4), anti Programmed death-1 (anti-PD1), anti Programmed death ligand 1 (anti-PD-L1), anti Programmed death ligand 2 (anti-PD-L2), anti-CD137, anti-CD40, anti-OX40 antibodies.

Related studies

NCT07645690 · Unresectable or Metastatic Clear Cell Renal Cell Carcinoma

NCT06661720 · Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), and more

NCT06863311 · Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, and more

NCT04659343 · Kidney Cancer, Renal Cell Carcinoma Metastatic, and more

NCT06500455 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, and more

Phase I Biomarker Study (BMS-936558)